Journal
SURVEY OF OPHTHALMOLOGY
Volume 60, Issue 2, Pages 93-105Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.survophthal.2014.07.001
Keywords
glaucoma; stem cell; retinal ganglion cell; trabecular meshwork; neuroprotection
Categories
Ask authors/readers for more resources
In recent years there has been substantial progress in developing stem cell treatments for glaucoma. As a downstream approach that targets the underlying susceptibility of retinal ganglion and trabecular meshwork cells, stem cell therapy has the potential to both replace lost, and protect damaged, cells by secreting neurotrophic factors. A variety of sources, including embryonic cells, adult cells derived from the central nervous system, and induced pluripotent stem cells show promise as therapeutic approaches. Even though safety concerns and ethical controversies have limited clinical implementation, some institutions have already commercialized stem cell therapy and are using direct-to-consumer advertising to attract patients with glaucoma. We review the progress of stem cell therapy and its current commercial availability. (C) 2015 Elsevier Inc. All rights reserved,
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available